Standard monitoring
OtherAdministration of fluids and vasoactive drugs guided by standard vital signs monitoring
NCT Number: NCT07101991
This study aims to assess the safety and efficacy of GDHT using the non-invasive Starling™ SV System in elective neurosurgery. The tested group of patients (n=70) will be compared with a control group (n=70), where hemodynamic management will be guided by standard vital signs monitoring.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Patients undergoing major surgery are at risk for inadequate intravascular volumes and therefore inadequate tissue perfusion and oxygen delivery. Especially in neurosurgery, fluid management can be a challenge. In many surgical areas, such as orthopedics, gynecology or abdominal surgery, goal-directed fluid therapy is used with the aim of reducing postoperative complications. Current knowledge regarding effect of the goal-directed therapy in neurosurgery is limited.
This is a multicenter, prospective, randomized, controlled study that compares two approaches to fluid management in elective brain surgery. Patients scheduled for brain surgery will be screened whether they meet the inclusion criteria and after obtaining informed consent, the patient will be randomized to one of two study arms.
In the first (standard) arm standard vital signs monitoring will be used during the surgery and perioperative fluid management and administration of vasopressors will be guided by the decision of the attending anaesthetist.
In the second (GDT) arm perioperative fluid management and administration of vasopressors will be guided by a non-invasive hemodynamic monitor STARLINK™SV, which will be introduced in addition to standard monitoring.
The primary outcome is the incidence of adverse events and reactions according to following Adverse Events of Special Interest (AESI) in both study groups and their comparison. The secondary outcome is to investigate the efficacy and additional safety parameters of GDHT guided by non-invasive advanced hemodynamic monitoring versus hemodynamic management guided by standard vital signs monitoring.
This study will enroll 140 patients in total, 70 in each group. After completion of enrolment of patients the statistical analysis will be performed.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Subjects will be eligible for the trial if they meet all of the following criteria:
Exclusion criteria
Subjects will not be eligible for the trial if they meet any of the following criteria:
Administration of fluids and vasoactive drugs guided by standard vital signs monitoring
Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring
Time frame: 28 days
Defined according to Kidney Disease Improving Global Outcomes (KDIGO) guidelines: Stage 1: serum creatinine 1.5-1.9 times baseline value within 7 days or ≥27 µmol l-1 (0.3 mg dl-1) increase within 48 h; urine output ≤0.5 ml kg-1 h-1 for 6-12 h Stage 2: serum creatinine 2.0-2.9 times baseline value within 7 days; urine output ≤0.5 ml kg-1 h-1 for 12 h Stage 3: serum creatinine 3.0 times baseline within 7 days or increase in serum creatinine to ≥354 µmol l-1 (≥4.0 mg.dl1 with an acute rise of > 44 mmol l-1 (0.5 mg/dl-1) or initiation of renal replacement therapy or in patients < 18 years, decrease in eGFR (estimated Glomerular Filtration Rate) to < 35 ml min-1 per 1.73m2; urine output ≤0.3 ml kg1 h-1 for 24 h or anuria for 12 h.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
The Berlin definition of Respiratory Distress Syndrome:
Timing: Within one week of a known clinical insult or new or worsening respiratory symptoms and Chest imaging: Bilateral opacities not fully explained by effusions, lobar/lung collapse or nobles and Origin of oedema: Respiratory failure not fully explained by cardiac failure or fluid overload.
Need objective assessment (e.g. echocardiography) to exclude hydrostatic oedema if no risk factor is presented and Oxygenation disorder: mild: PaO2 (partial pressure of oxygen in arterial blood):FIO2 (Fraction of Inspired Oxygen) between 26.7 and 40.0 kPa (kilopascal) (200-300mmHg) with PEEP (Positive End-Expiratory Pressure) or CPAP (Continuous Positive Airway Pressure) ≥5 cmH2O (centimeters of water). Moderate: PaO2:FIO2 between 13.3 and 26.6 kPa (100- 200 mmHg) with PEEP ≥5 cmH2O. Severe: PaO2:FIO2 ≤13.3 kPa (100mmHg) with PEEP ≥5 cmH2O.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Defined as electrocardiograph (ECG) evidence of cardiac rhythm disturbance. AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Cessation of cardiac mechanical activity, as confirmed by the absence of signs of circulation. AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Defined as evidence of fluid accumulation in the alveoli due to poor cardiac function.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
A new blood clot or thrombus within the venous system. Appropriate diagnostic tests include ultrasound, venography, CT or MRI venography. Plasma D-dimer measurement is not recommended as a diagnostic test in the first three weeks following surgery.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
A new blood clot or thrombus within the pulmonary arterial system. AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Clinical or endoscopic evidence of blood in the gastrointestinal tract. AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Infection where there is strong clinical suspicion of infection but the source has not been confirmed because clinical information suggests more than one possible site, meeting two or more of the following criteria: core temperature < 36°C or >38°C; white cell count >12×109 l-1 or < 4×109 l-1, respiratory rate >20 breaths per minute or PaCO2 < 4.7 kPa (35mmHg); pulse rate >90 beats per minute.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Infection which meets at least one of the following criteria which should not be related to infection at another site:
Time frame: 28 days
Defined as increase in serum cardiac biomarker values (preferably cardiac troponin) with at least one value above the 99th percentile upper reference limit and at least one of the following criteria: symptoms of ischaemia; new or presumed new significant ST segment or T wave ECG changes or new left bundle branch block; development of pathological Q waves on ECG; radiological or echocardiographic evidence of new loss of viable myocardium or new regional wall motion abnormality; identification of an intracoronary thrombus at angiography or autopsy.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Definition: Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease):
(1) fever (>38°C) with no other recognised cause (2) leucopaenia (white cell count < 4 × 109 l-1) or leucocytosis (white cell count >12 × 109 l-1) (3) for adults >70 years old, altered mental status with no other recognised cause; and at least two of the following:
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Failure to tolerate solid food or defecate for three or more days after surgery.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Blood loss within 72 h after the start of surgery which would normally result in transfusion of blood.
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
An embolic, thrombotic or haemorrhagic cerebral event with persistent residual motor, sensory or cognitive dysfunction (e.g. hemiplegia, hemiparesis, aphasia, sensory deficit, impaired memory).
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Brain oedema confirmed on CT or MRI scan. AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
A superficial incisional surgical site infection is defined as one which meets the following criteria:
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
AESI will be analysed descriptively and compared between study groups.
Time frame: 28 days
Infection which involves any part of the body excluding the fascia or muscle layers and meets the following criteria:
Time frame: 28 days
A positive urine culture of ≥105 colony forming units ml-1 with no more than two species of micro-organisms, and with at least one of the following symptoms or signs: fever (>38°C), urgency, frequency, dysuria, suprapubic tenderness, costovertebral angle pain or tenderness with no other recognised cause. Each of these criteria should be identified within a 24-h period.
AESI will be analysed descriptively and compared between study groups.
Time frame: During the surgery (hours)
Duration of surgery (min) - will be analysed descriptively and compared between study arms
Time frame: Days (up to 28)
LOS (Length of stay, day of admission - day of discharge will be counted as 1 day) - will be calculated as a number of days between admission and discharge, analysed descriptively and compared between study groups.
Time frame: Days (up to 28)
ICU LOS (day of admission - day of discharge will be counted as 1 day) - will be calculated as a number of days between admission to the ICU and discharge from the ICU, analysed descriptively and compared between study groups.
Time frame: 28 days after randomization
28-day mortality (number of patients who are not alive 28 days after randomization) will be evaluated as a number and percentage of patients who are not alive 28 days after randomization and compared between study arms.
Time frame: 28 days
Descriptive analysis of the incidence of any adverse events and reactions
Time frame: During the surgery and 24 hours post operation
MAP (mmHg; before, after surgery) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
HR (Bpm; before, after surgery) will be analysed descriptively and compared between study arms.
Time frame: During the surgery (hours)
SVV (%; before, after surgery will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Number of episodes of hypotension will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Number of vasopressor administrations will be analysed descriptively and compared between study arms.
Time frame: 24 hours
Hemoglobin (g/l; before, after surgery and 24 hours after surgery) - will be analysed descriptively and compared between study arms.
Time frame: 24 hours
Plasma lactate level (mmol/L; before, after surgery and 24 hours after surgery) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Volume of blood loss (ml/kg; during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Urinary output (ml/kg/hod; during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Number of administered units of packed RBC (during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Number of subjects receiving transfusion (during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Crystalloid and colloid solutions consumption (type and total volume of infusion during surgery and in the 24-hour postoperative period) will be analysed descriptively and compared between study arms.
Time frame: During the surgery and 24 hours post operation
Boluses of crystalloids (ml; during surgery) will be analysed descriptively and compared between study arms.
Contact information is provided by the study sponsor or research team.
Ondřej Hrdý, M.D.
CONTACT
Roman Gál, prof.
CONTACT
Brno University Hospital
Other
Effects of Goal-directed Fluid Management Guided by a Non-invasive Device on the Incidence of Postoperative Complications in Neurosurgery: a Multicenter, Prospective, Randomized, Controlled Study
Acronym: NCHGDT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07655414
Surgery Complications
Ottawa, Ontario, Canada
View Trial DetailsNCT07662980
Diabetes Mellitus, Endocrine System Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT07604662
Acute Kidney Injury, Anesthesia
San Francisco, California, United States
View Trial DetailsNCT07506889
Behavior, Disease
Jönköping, Sweden
View Trial Details